Market Capitalization

The full commercial launch of the Aeros Modular Stem System brings advanced 3D printing and a novel surgical approach to the competitive ankle replacement market.

With assets double its market value, Base Carbon's CEO claims it's no junior firm. A deep dive into its finances and high-integrity carbon projects.

NeuPath Health aims to pay executive bonuses with shares after a major financial recovery, but the related-party deal now faces a crucial shareholder vote.

Facing Nasdaq delisting, Chinese IT firm Hitek Global enacts a massive reverse stock split. Is this a strategic reset or a desperate last stand for survival?

As it turns six, crypto platform BYDFi expands into traditional finance, bolsters global regulatory compliance, and launches a $1M anniversary event.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

Sieve Capital launches a public campaign against Americold Chairman Mark Patterson, citing a -50% return and a history of poor corporate governance.

The NFL star's multi-year deal with the iconic American brand signals a major shift in athlete endorsements and a strategic play for cultural relevance.

The massive C$5.15 billion deal transforming Plains into a crude oil pure-play and Keyera into an NGL giant faces a delay amid a Competition Bureau review.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.

Starcloud is now Y Combinator's fastest unicorn. Its audacious plan to build data centers in orbit has attracted top VCs and sparked a new space race for AI.

A new strategic partnership gives Kudu's global network of investment firms access to elite operational tech, signaling a new era of competition.

Allspring's closed-end funds offer tempting yields, but tiny shifts in their monthly payouts reveal a complex story of risk, return, and capital erosion.

The digital infrastructure firm secured new funding for expansion, but a steep discount in its offering has rattled investors and sent its share price plunging.

The pharma firm hit pause on a crucial reverse stock split needed to keep its Nasdaq listing, citing "timing considerations" and raising investor questions.

EnerSys will unveil its strategic framework and technology roadmap, outlining its plan to navigate the energy transition and capitalize on market growth.

Cocoa prices are falling, but your chocolate bar costs more. Discover why consumers are embracing this shift by reaching for premium, pricier treats.

With its 32nd straight dividend hike and a $100M buyback, Wiley leverages strong Q3 results and AI momentum to underscore its financial health.

Healthcare powerhouse Terri Cooper joins Morphic Medical's board, a strategic move to navigate clinical trials for its non-surgical RESET diabetes therapy.